A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

INTRODUCTION: A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) were assessed for potential benefit. MATERIAL AND METHODS: In a randomized phase II study, R/M HNSCC patients were treated with cetuximab 400mg/m(2)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oral Oncol
Main Authors: Gilbert, Jill, Schell, Michael J., Zhao, Xiuhua, Murphy, Barbara, Tanvetyanon, Tawee, Leon, Marino E., Hayes, D. Neil, Haigentz, Missak, Saba, Nabil, Nieva, Jorge, Bishop, Justin, Sidransky, David, Ravi, Rajani, Bedi, Atul, Chung, Christine H.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459134/
https://ncbi.nlm.nih.gov/pubmed/25593015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2014.12.011
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki